Is Trump giving the EU higher drug prices too?
From the article:
Through single-payer health care systems the EU is able to regulate consumer costs at reasonable levels. It also makes decisions about what new drugs are worth spending taxpayer money on and how to fairly value them.
Without looking at the actual issue — that pharmaceutical companies are allowed to charge whatever amount they want on the US market — the problem will not be solved. As Rachel Sachs, associate law professor at Washington University in St. Louis argues: "The administration is proposing to take very few actions that would impact pharmaceutical companies' bottom lines. Many of the actions they have proposed are repeats of those they've presented on other occasions, and even those actions still appear to be far in the future."
Read more here!health care finance health care reform health law policy international pharmaceuticals rachel sachs